Cis-Diamminedichloroplatinum in the Treatment of Advanced Epidermoid Carcinoma of the Penis: A Southwest Oncology Group Study
- 1 January 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 141 (1) , 66-67
- https://doi.org/10.1016/s0022-5347(17)40590-8
Abstract
A total of 26 patients with biopsy proved epidermoid carcinoma of the penis (Jackson stage III or IV) with measurable disease, no prior chemotherapy and adequate renal function received 50 mg. per M.2 cis-diamminedichloroplatinum intravenously on days 1 and 8 of 28-day cycles. There were 4 partial responses (15.4 per cent), with a response duration of 1 to 3 months. The median survival was 4.7 months. This agent cannot be recommended as treatment for advanced epidermoid carcinoma of the penis using this particular dose and schedule.This publication has 13 references indexed in Scilit:
- Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.Journal of Clinical Oncology, 1987
- Sequential Trials of Methotrexate, Cisplatin and Bleomycin for Penile CancerJournal of Urology, 1984
- Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinomaCancer, 1979
- Carcinoma of the Penis: a Review of 42 CasesBritish Journal of Urology, 1977
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977
- Bleomycin, an Antitumor AntibioticAnnals of Internal Medicine, 1972
- The treatment of carcinoma of the penisBritish Journal of Surgery, 1966
- Carcinoma of the penis in uganda and kenya africansCancer, 1963
- Clinical evaluation of cancer chemotherapy with 5-fluorouracilCancer, 1961